Clinical Trial and Other Sourcing Agreements
• Sponsor Master Services Agreements
• Clinical trials management
♦ Investigators
♦ Contract Labs
♦ IRBs
♦ Active Pharmaceutical Ingredient (API) supply sourcing
♦ Component sourcing deals
♦ Medical advisory boards
Commercial Agreements – FDA Issues Presented By:
♦ Co-Development Agreements
♦ Acquisitions involving pipeline products
♦ Clinical data ownership
Good Clinical Practice (“GCP”) Compliance & Training
♦ HIPAA and privacy considerations
• implementing procedures in clinical trials
• consents
♦ State regulatory requirements
Clinical Trial Protocol Reviews
Informed Consent Reviews
Financial Disclosure Requirements – Compliance and Strategies
♦ Federal: FDA & HHS
♦ Institutional (e.g., university, hospital)
♦ Clinical trial design to minimize conflicts
|
Investigational New Drug (IND) and Device (IDE) Submissions
♦ Pre-IND and IDE meetings
• preparation
• submissions
• initial filing
• maintenance during life of the IND – changes
♦ PDUFA, MDUFMA and Application Fees
♦ Device Reclassification Petitions – easing the burden
• “De Novo” petitions for truly “new” technologies
• Traditional for pre-’76 devices
New Drug Applications (NDAs), Biologics License Applications
(BLAs), Abbreviated NDAs (ANDAs), Device Pre-Market
Approval (PMAs) Applications and Pre-Market Notification
Submissions (510k’s)
♦ Counseling on requirements
♦ Strategies to maximize approval process
♦ Responding to FDA deficiency letters
♦ Achieving binding agreements with FDA on clinical design
FDA Liaison & Meetings
♦ End-of-Phase meetings (I, II, III)
♦ Advisory Committee preparation and meetings
Promotion and Advertising During R&D
♦ Reviews
♦ Training
♦ Audits
Emerging FDA Issues & Their Impact on Development Plans
♦ Comment preparation on FDA initiatives
♦ Legislative responses
♦ Client-generated strategic initiatives
State Law Issues
♦ Privacy
♦ Medical Records
|
